There were 40 hormone receptor (HR)+ (human epidermal growth factor receptor 2) HER2- breast cancer, 40 HER2+ cancers and 10 triple negative breast cancer (TNBC) patients based on the primary tumor. This evidence concerns the gene ERBB2 and neoplasm.